Agilent Technologies, Inc. (A) Earnings Call Transcripts

Agilent Technologies, Inc.'s Latest Earnings Call - June 3, 2026

Agilent Technologies reported a strong Q2 2026, achieving revenue growth of 6.3% year-over-year and 14% EPS growth, exceeding management's guidance. The company experienced broad growth across its segments, particularly in diagnostics and semiconductors, with notable margin expansion of 130 basis points. Management maintained a positive outlook for the remainder of the fiscal year, signaling continued momentum and innovation-driven growth, particularly with new product launches and market share gains.

Reported metrics

Guidance from management

Management maintained a positive outlook for the second half of 2026, expecting continued growth driven by innovation and market share gains, particularly in the Advanced Therapeutics Division and diagnostics.

What management said

Yes. I think, look, if you think about it, semis represents about a $400 million market opportunity for us. By the way, it's not just ICP-MS, it's GCMS products that are in those fabs as well. And our total semi exposure is about 3% to 4% of Agilent's revenue. So I think, overall, we grew double digits in that side of it, we expect that to continue. So I think it's going to be above that in terms of growth rates as...

Yes. No, I think we saw broad strength across it. I think China was a little bit slow for us and we were expecting that, but we saw broad strength in the Americas, Europe and Asia outside China. .

What analysts pressed on

Analysts expressed concerns about the softness in the China market and the potential impact of macroeconomic factors on future growth. There were questions regarding the timing of AI initiatives translating into revenue and the overall sustainability of growth in the diagnostics segment.

Main topics on the call

• Strong Revenue and EPS Growth — Agilent reported a revenue growth of 6.3% and an EPS growth of 14%, which was 'well ahead of guidance.' This performance reflects strong demand across various segments, particularly in diagnostics and semiconductors.
• Market Share Gains — Management highlighted 'outsized share gains' across instrument product lines, particularly in LC spectroscopy and GC. This broad-based growth is attributed to improved commercial execution and innovation.
• Innovation and New Product Launches — The launch of the 9500 ICP-MS and advancements in the Infinity III platform are expected to drive a 'tech refresh' among existing customers, particularly in the semiconductor market where Agilent holds an 80% market shar...
• Guidance for Future Growth — Management maintained a positive outlook, indicating that the second half of 2026 is expected to continue the momentum with visibility into growth in the Advanced Therapeutics Division and a strong pipeline of new produc...

Read the full Agilent Technologies, Inc. transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 76 Agilent Technologies, Inc. earnings call transcripts on record, spanning January 14, 2020 to June 3, 2026. Based on this history, Agilent Technologies, Inc. reports quarterly. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

A

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

76

First call

January 14, 2020

Most recent

June 3, 2026

Reporting cadence

quarterly